Results from a population-based cohort study indicate that patient comorbidities including chronic kidney disease are much more strongly associated with AKI and that treatment with either an ACE Inhibitor or an ARB is only associated with a small increase in AKI risk.27That is, younger patients with limited comorbidity (eg, on ACEI for treatment of hypertension) have a low absolute risk of AKI, while patients living with multimorbidity in whom there may be professional concerns about ensuring effective risk communication, have a much higher risk of AKI.27 The gene discussed is ACE; the disease is acute kidney injury.